Pralmorelin
Plasma GH levels after a single administration of pralmorelin were greater than 15 μg / L in healthy subjects, while less than 15 μg/L in patients with severe GHD 20, which led to the approval of pralmorelin for the diagnosis of GHD in Japan 2004 [28]. Also, pralmorelin has been shown to stimulate growth speed after 8 months of intermittent therapy in children with GHD with intact hypothalamic-pituitary (H-P) axes [28]. Although pralmorelin has reached Phase II clinical trials for the treatment of short statues, development has been halted. This was probably because pralmorelin did not increase plasma GH levels sufficiently in patients with GHD.